The TIGIT/CD226 axis regulates human T cell function - PubMed (original) (raw)
The TIGIT/CD226 axis regulates human T cell function
Ester Lozano et al. J Immunol. 2012.
Abstract
T cell Ig and ITIM domain (TIGIT) is a newly identified receptor expressed on T cells that binds to CD155 on the dendritic cell surface, driving them to a more tolerogenic phenotype. Given that TIGIT contains an ITIM motif in its intracellular domain and considering the potential importance of the TIGIT/CD226 pathway in human autoimmune disease, we investigated the specific role of TIGIT in human CD4(+) T cells. Using an agonistic anti-TIGIT mAb, we demonstrate a direct inhibitory effect on T cell proliferation with a decrease in expression of T-bet, GATA3, IFN regulatory factor 4, and retinoic acid-related orphan receptor c with inhibition of cytokine production, predominantly IFN-γ. Knockdown of TIGIT expression by short hairpin RNA resulted in an increase of both T-bet and IFN-γ mRNA and protein expression with concomitant decrease in IL-10 expression. Increases in IFN-γ with TIGIT knockdown could be overcome by blocking CD226 signaling, indicating that TIGIT exerts immunosuppressive effects by competing with CD226 for the same CD155 ligand. These data demonstrate that TIGIT can inhibit T cell functions by competing with CD226 and can also directly inhibit T cells in a T cell-intrinsic manner. Our results provide evidence for a novel role of this alternative costimulatory pathway in regulating human T cell responses associated with autoimmune disease.
Conflict of interest statement
Disclosures
The authors have no conflicting financial of interests.
Figures
Figure 1
Upregulation of TIGIT, CD226 and CD155 in human CD4+ T cells after activation. (A) Dot plots displaying the cell surface expression of TIGIT, CD226, CD155 and CD112 on naïve CD4+ T cells (CD45RO−) and memory T cells (CD45RO+) ex vivo and after activation with anti-CD3 and anti-CD28 for 2 days. (B) Kinetics of gene expression of TIGIT, CD226 and their ligands CD155 and CD112 on sorted memory T cells (CD4+ CD62L+ CD25lowCD45RO+). Data are normalized relative to beta 2 microglobulin. Data are representative of four donors.
Figure 2
TIGIT cell-intrinsic signaling inhibits T cell proliferation. (A) Proliferation of human CD4+ T cells labeled with CFSE and activated with anti-CD3 and anti-CD28 with plate-bound agonistic anti-TIGIT or isotype-matched control antibody. On day 5, CFSE dilution was analyzed by flow cytometry after gating on viable cells. (B) Percentages of dividing cells after activation represent the CFSElow cells (n=8). Mean values are shown ± SD. (C) Viability was assessed in all the experiments. (D) No significant differences were observed in the frequency of viable cells. (E) Flow cytometry of the surface expression of CD25 and CD69 as markers of activation of human CD4+ T cells activated in presence of agonistic anti-TIGIT or isotype control, assessed on day 5 after activation. (F) Sorting strategy for memory T cells (CD4+ CD62L+ CD25low CD45RO+) purity. (G) CFSE proliferation assay of memory T cells in the presence of agonistic anti-TIGIT. Proliferation was assessed on day 5 after gating on viable cells. Percentages of proliferating cells are depicted above the histograms. (H) Quantitative real-time RT-PCR analysis of relative IL-2 gene expression in FACS-sorted memory T cells. Data shown are representative of four different donors.
Figure 3
TIGIT cell-intrinsic signaling inhibits T cell cytokine production. (A) Time course of transcription factors expression in memory T cells stimulated with IL-12 (Th1) IL-4 (Th2), TGFβ+IL-4 (Th9) and TGFβ+IL-1β/IL-6/IL-21 (Th17) and cultured in presence agonistic anti-TIGIT or isotype control for 3 days. (B) Intracellular cytokine staining for IFNγ, IL-13, IL-4, IL-9 and IL-17 in memory T cells cultured in the same conditions than A for 4 days. Data shown are representative of at least four independent experiments.
Figure 4
Knockdown of CD226 expression in human CD4+ T cells. (A) CD226 gene expression in human CD4+ T cells transfected with specific siCD226 or negative siRNA, assessed by real-time RT-PCR on day 1 and 2 after electroporation. (B) Flow cytometry of the surface expression of CD226 and IFNγ intracellular staining on human CD4+ T cells transfected with siRNA or control, and stimulated with PMA and ionomycin for 4 hr in the presence of GolgiStop. Cells were stained with LIVE/DEAD Fixable Dead Cell Stain Kit before fixation to allow gating on viable cells. (C) Measurement of IFNγ in the supernatants of cells transfected with siCD226 or negative siRNA. (D) Flow cytometry of the surface expression of CD226 and IFNγ intracellular staining on CD4+ T cells transfected as in B, and then stimulated with IL-12 for 3 days. (E) Flow cytometry of the surface expression of CD226 and IFNγ intracellular staining on human CD4+ T cells transduced with shCD226 or control by lentiviral transduction. Data are representative of three independent experiments. Mean values are shown ± SEM.
Figure 5
Knockdown of TIGIT expression in human CD4+ T cells by lentiviral transduction with two specific shRNAs. (A) Quantitative real-time RT-PCR analysis of relative TIGIT gene expression in human CD4+ T cells infected with lentivirus containing two TIGIT-specific shRNA sequences or an empty vector, assessed on day 3 after puromycin selection. (B) Gene expression of other negative regulators, CTLA-4 and PD-1 was measured to exclude non-target effects. (C) Relative quantification of T-bet (Tbx21), IFNγ and IL-10 mRNA in T cells transduced with shTIGIT-1, shTIGIT-2 or an empty vector. (D) Flow cytometry of the surface expression of TIGIT and IFNγ intracellular staining on human CD4+ T cells infected with TIGIT-specific shRNA or control, selected with puromycin and stimulated with PMA and ionomycin for 4 hr in the presence of GolgiStop. Cells were stained with LIVE/DEAD Fixable Dead Cell Stain Kit before fixation to allow gating on viable cells. Data are representative of four independent experiments with three individual donors. (E) Levels of IL-10 in the supernatants derived from the same cultures as in C quantified by ELISA. Mean values are shown ± SEM.
Figure 6
Blockade of CD226 signaling with anti-CD226 or anti-CD155 decreased the effects of TIGIT knockdown. (A) Quantitative real-time PCR analysis of relative T-bet (Tbx21) expression in TIGIT-depleted CD4+ T cells incubated for 4 days in the presence of increasing concentrations of plate-bound blocking anti-CD226, blocking anti-CD155 or isotype control IgG. (B) IFNγ gene expression. (C) IL-10 gene expression in the same conditions than in A. Data shown are representative of four different donors.
Similar articles
- TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells.
Zhang D, Hu W, Xie J, Zhang Y, Zhou B, Liu X, Zhang Y, Su Y, Jin B, Guo S, Zhuang R. Zhang D, et al. Biochim Biophys Acta Mol Basis Dis. 2018 Sep;1864(9 Pt B):3085-3098. doi: 10.1016/j.bbadis.2018.06.022. Epub 2018 Jun 28. Biochim Biophys Acta Mol Basis Dis. 2018. PMID: 29960041 - Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226.
Fuhrman CA, Yeh WI, Seay HR, Saikumar Lakshmi P, Chopra G, Zhang L, Perry DJ, McClymont SA, Yadav M, Lopez MC, Baker HV, Zhang Y, Li Y, Whitley M, von Schack D, Atkinson MA, Bluestone JA, Brusko TM. Fuhrman CA, et al. J Immunol. 2015 Jul 1;195(1):145-55. doi: 10.4049/jimmunol.1402381. Epub 2015 May 20. J Immunol. 2015. PMID: 25994968 Free PMC article. - The CD226/CD155 interaction regulates the proinflammatory (Th1/Th17)/anti-inflammatory (Th2) balance in humans.
Lozano E, Joller N, Cao Y, Kuchroo VK, Hafler DA. Lozano E, et al. J Immunol. 2013 Oct 1;191(7):3673-80. doi: 10.4049/jimmunol.1300945. Epub 2013 Aug 26. J Immunol. 2013. PMID: 23980210 Free PMC article. - DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
Shibuya A, Shibuya K. Shibuya A, et al. Int Immunol. 2021 Nov 25;33(12):687-692. doi: 10.1093/intimm/dxab085. Int Immunol. 2021. PMID: 34694361 Review. - CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
Liu L, You X, Han S, Sun Y, Zhang J, Zhang Y. Liu L, et al. Oncol Rep. 2021 Mar;45(3):835-845. doi: 10.3892/or.2021.7943. Epub 2021 Jan 19. Oncol Rep. 2021. PMID: 33469677 Review.
Cited by
- TGF-β-mediated crosstalk between TIGIT+ Tregs and CD226+CD8+ T cells in the progression and remission of type 1 diabetes.
Zhong T, Li X, Lei K, Tang R, Deng Q, Love PE, Zhou Z, Zhao B, Li X. Zhong T, et al. Nat Commun. 2024 Oct 15;15(1):8894. doi: 10.1038/s41467-024-53264-8. Nat Commun. 2024. PMID: 39406740 Free PMC article. - Prognostic Protein Biomarker Screening for Thyroid Carcinoma Based on Cancer Proteomics Profiles.
Xie P, Yin Q, Wang S, Song D. Xie P, et al. Biomedicines. 2024 Sep 10;12(9):2066. doi: 10.3390/biomedicines12092066. Biomedicines. 2024. PMID: 39335579 Free PMC article. - The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy.
Murakami K, Ganguly S. Murakami K, et al. Front Immunol. 2024 Aug 2;15:1441730. doi: 10.3389/fimmu.2024.1441730. eCollection 2024. Front Immunol. 2024. PMID: 39156900 Free PMC article. Review. - Inhibition of CD226 Co-Stimulation Suppresses Diabetes Development in the NOD Mouse by Augmenting Tregs and Diminishing Effector T Cell Function.
Brown ME, Thirawatananond P, Peters LD, Kern EJ, Vijay S, Sachs LK, Posgai AL, Brusko MA, Shapiro MR, Mathews CE, Bacher R, Brusko TM. Brown ME, et al. bioRxiv [Preprint]. 2024 Jul 19:2024.07.16.603756. doi: 10.1101/2024.07.16.603756. bioRxiv. 2024. PMID: 39071293 Free PMC article. Preprint. - Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.
Yin N, Li X, Zhang X, Xue S, Cao Y, Niedermann G, Lu Y, Xue J. Yin N, et al. Signal Transduct Target Ther. 2024 May 22;9(1):126. doi: 10.1038/s41392-024-01826-z. Signal Transduct Target Ther. 2024. PMID: 38773064 Free PMC article. Review.
References
- Vijayakrishnan L, Slavik JM, Illes Z, Greenwald RJ, Rainbow D, Greve B, Peterson LB, Hafler DA, Freeman GJ, Sharpe AH, Wicker LS, Kuchroo VK. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity. 2004;20:563–575. - PubMed
- Maier LM, Hafler DA. Autoimmunity risk alleles in costimulation pathways. Immunol Rev. 2009;229:322–336. - PubMed
- Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ronningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SC. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003;423:506–511. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 NS024247-14/NS/NINDS NIH HHS/United States
- U19AI070352/AI/NIAID NIH HHS/United States
- U19 AI070352/AI/NIAID NIH HHS/United States
- P01AI03971/AI/NIAID NIH HHS/United States
- R01 NS024247/NS/NINDS NIH HHS/United States
- U19 AI070352-05/AI/NIAID NIH HHS/United States
- R01NS024247/NS/NINDS NIH HHS/United States
- P01 NS038037/NS/NINDS NIH HHS/United States
- P01NS038037/NS/NINDS NIH HHS/United States
- P01 AI039671/AI/NIAID NIH HHS/United States
- P01 NS038037-10/NS/NINDS NIH HHS/United States
- P01 AI039671-14/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials